TY  - JOUR
AU  - Núñez-Núñez, María
AU  - Casas-Hidalgo, Inmaculada
AU  - García-Fumero, Ricardo
AU  - Vallejo-Rodríguez, Inmaculada
AU  - Anguita-Santos, Francisco
AU  - Hernández-Quero, José
AU  - Cabeza-Barrera, José
AU  - Ruiz-Sancho, Andrés
PY  - 2018
DO  - 10.1136/ejhpharm-2018-001711
SN  - 2047-9956
UR  - https://hdl.handle.net/10668/26136
T2  - European journal of hospital pharmacy : science and practice
AB  - Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective...
LA  - en
KW  - clinical pharmacy
KW  - dalbavancin
KW  - infectious diseases
KW  - new antimicrobials
KW  - Aged
KW  - Aged, 80 and over
KW  - Anti-Bacterial Agents
KW  - Drug Labeling
KW  - Drug Resistance, Multiple, Bacterial
KW  - Female
KW  - Follow-Up Studies
KW  - Gram-Positive Bacterial Infections
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Teicoplanin
TI  - Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications.
TY  - research article
VL  - 27
ER  -